Hint mode is switched on Switch off
For swift navigation between sections

Organization: Qiagen
LEI 54930036WK3GMCN17Z57

Organization name
Qiagen N.V.
Country name
Netherlands
Country of registration
Netherlands
Industry
Pharmaceutical Preparation and Biotechnology
Bond debt
1,000 mln USD

explore the most comprehensive database

800 000

bonds globally

Over 400

pricing sources

80 000

stocks

9 000

ETF

track your portfolio in the most efficient way
Bond Search
Watchlist
Excel ADD-IN
Get access
×

— Are you looking for the complete & verified bond data?

— We have everything you need:

full data on over 700 000 bonds, stocks & ETFs; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; user-friendly interface; available anywhere via Website, Excel Add-in and Mobile app.

Register
×

Why

You will have detailed descriptive & pricing data for 650K bonds, 76K stocks, 8K ETFs
Get full access to the platform from any device & via Cbonds app
Enhance your portfolio management with Cbonds Excel Add-in
Build yield maps, make chart comparison within a click
Don't wait any longer — start using Cbonds today! Register

Latest data on

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Qiagen is a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. Consolidated under the Dutch holding Qiagen N.V., the company operates more than 35 offices in over 20 countries. Qiagen’s shares are listed at the technology-focused U.S. stock exchange Nasdaq (using ticker QGEN) and at the Frankfurt Stock Exchange in the Prime Standard (using ticker QIA). Peer M. Schatz is the company’s Chief Executive Officer. The main operative headquarters are located in Hilden, Germany (near Düsseldorf).

Awards

News

19/01/2022 QIAGEN N.V. to release results for Q4 2021 and Full-Year of 2021
20/10/2021 QIAGEN N.V. to Release Results for Q3 2021 and First Nine Months of 2021
12/07/2021 QIAGEN N.V. Conference Call on July 13 to Discuss Preliminary Q2 2021 Results
08/11/2018 New bond issue: Qiagen issued international bonds (XS1908221507) with a 1% coupon for USD 500.0m maturing in 2024
08/09/2017 New bond issue: Qiagen issued international bonds with a 0.5% coupon for USD 400.0m maturing in 2023
All organization news

Documentation

IFRS/US GAAP reports

2023
IV q eng
2022
IV q eng
2021
I q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
IV q eng
2016
IV q eng
2015
IV q eng
2014
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Latest issues

Show all

Bond debt by currency

Show more Hide

Codes

  • LEI
    54930036WK3GMCN17Z57
  • SIC
    2836 BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
  • CIK
    0001015820

Credit and ESG Ratings

Macroeconomic Indicators - Qiagen

Registration is required to get access.